Novel chemotherapeutic and targeted agents in metastatic colorectal cancer: the time has arrived (Q35594038)

9 August 2017

1 reference

title

Novel chemotherapeutic and targeted agents in metastatic colorectal cancer: the time has arrived (English)

1 reference

9 August 2017

1 reference

1 reference

metastatic colon cancer

1 reference

Bert H O'Neil

1

1 reference

9 August 2017

Richard M Goldberg

series ordinal

2

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 December 2003

1 reference

Expert Opinion on Investigational Drugs

9 August 2017

published in

1 reference

9 August 2017

volume

12

1 reference

9 August 2017

issue

12

1 reference

9 August 2017

page(s)

1939-1949

1 reference

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1939

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1939

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1939

Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1939

A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1939

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1939

Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B12 as Front-Line Therapy in Malignant Pleural Mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1939

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1939

Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1939

Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1939

Role of an anti-epidermal growth factor receptor in treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1939

Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1939

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1939

CI-1033, a pan-erbB tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1939

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.12.1939

10.1517/13543784.12.12.1939

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference